Literature DB >> 16724053

Ras, PI(3)K and mTOR signalling controls tumour cell growth.

Reuben J Shaw1, Lewis C Cantley.   

Abstract

All eukaryotic cells coordinate cell growth with the availability of nutrients in their environment. The mTOR protein kinase has emerged as a critical growth-control node, receiving stimulatory signals from Ras and phosphatidylinositol-3-OH kinase (PI(3)K) downstream from growth factors, as well as nutrient inputs in the form of amino-acid, glucose and oxygen availability. Notably, components of the Ras and PI(3)K signalling pathways are mutated in most human cancers. The preponderance of mutations in these interconnected pathways suggests that the loss of growth-control checkpoints and promotion of cell survival in nutrient-limited conditions may be an obligate event in tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16724053     DOI: 10.1038/nature04869

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  783 in total

1.  Nucleolar targeting of the chaperone hsc70 is regulated by stress, cell signaling, and a composite targeting signal which is controlled by autoinhibition.

Authors:  Piotr Bański; Hicham Mahboubi; Mohamed Kodiha; Sanhita Shrivastava; Cynthia Kanagaratham; Ursula Stochaj
Journal:  J Biol Chem       Date:  2010-05-10       Impact factor: 5.157

2.  The Rheb-mTOR pathway is upregulated in reactive astrocytes of the injured spinal cord.

Authors:  Simone Codeluppi; Camilla I Svensson; Michael P Hefferan; Fatima Valencia; Morgan D Silldorff; Masakatsu Oshiro; Martin Marsala; Elena B Pasquale
Journal:  J Neurosci       Date:  2009-01-28       Impact factor: 6.167

Review 3.  PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects.

Authors:  Vera P Krymskaya; Elena A Goncharova
Journal:  Cell Cycle       Date:  2009-02-06       Impact factor: 4.534

4.  Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo.

Authors:  Marianne M Stanford; Mae Shaban; John W Barrett; Steven J Werden; Philippe-Alexandre Gilbert; Joe Bondy-Denomy; Lisa Mackenzie; Kevin C Graham; Ann F Chambers; Grant McFadden
Journal:  Mol Ther       Date:  2007-11-13       Impact factor: 11.454

5.  Baicalein Targets GTPase-Mediated Autophagy to Eliminate Liver Tumor-Initiating Stem Cell-Like Cells Resistant to mTORC1 Inhibition.

Authors:  Raymond Wu; Ramachandran Murali; Yasuaki Kabe; Samuel W French; Yi-Ming Chiang; Siyu Liu; Linda Sher; Clay C Wang; Stan Louie; Hidekazu Tsukamoto
Journal:  Hepatology       Date:  2018-10-09       Impact factor: 17.425

6.  mTORC1 inhibition restricts inflammation-associated gastrointestinal tumorigenesis in mice.

Authors:  Stefan Thiem; Thomas P Pierce; Michelle Palmieri; Tracy L Putoczki; Michael Buchert; Adele Preaudet; Ryan O Farid; Chris Love; Bruno Catimel; Zhengdeng Lei; Steve Rozen; Veena Gopalakrishnan; Fred Schaper; Michael Hallek; Alex Boussioutas; Patrick Tan; Andrew Jarnicki; Matthias Ernst
Journal:  J Clin Invest       Date:  2013-01-16       Impact factor: 14.808

7.  Mutations in critical domains confer the human mTOR gene strong tumorigenicity.

Authors:  Avaniyapuram Kannan Murugan; Ali Alzahrani; Mingzhao Xing
Journal:  J Biol Chem       Date:  2013-01-15       Impact factor: 5.157

8.  Inhibition of Mammalian target of rapamycin by rapamycin causes the regression of carcinogen-induced skin tumor lesions.

Authors:  Panomwat Amornphimoltham; Kantima Leelahavanichkul; Alfredo Molinolo; Vyomesh Patel; J Silvio Gutkind
Journal:  Clin Cancer Res       Date:  2008-12-10       Impact factor: 12.531

9.  Morphoproteomic evidence of constitutively activated and overexpressed mTOR pathway in cervical squamous carcinoma and high grade squamous intraepithelial lesions.

Authors:  Wei Feng; Xiuzhen Duan; Jinsong Liu; Jianguo Xiao; Robert E Brown
Journal:  Int J Clin Exp Pathol       Date:  2008-10-02

Review 10.  PI3K signaling in glioma--animal models and therapeutic challenges.

Authors:  Christine K Cheng; Qi-Wen Fan; William A Weiss
Journal:  Brain Pathol       Date:  2009-01       Impact factor: 6.508

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.